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tests. CONCLUSIONS: The instrument constitutes a single tool to assess both patient 
and physician perceptions of psoriasis severity and treatment effect. The availability 
of a shared instrument may improve treatment decision-making, reconciliating patient 
and physician perceptions. An observational study with 100 dermatologists and 561 
patients is planned to assess agreement between patient and clinician perceptions; 
scoring and psychometric properties will also be validated.
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OBJECTIVES: This research has been driven by the need for a quality of life (QoL) 
instrument that speciﬁ cally assesses physical appearance. The BeautyQol instrument 
is a multi-dimensional, self administered questionnaire, which has been in develop-
ment for over three years in 16 languages. METHODS: In the item generation phase, 
semi directive interviews were conducted in 309 subjects. In the second phase an 
acceptability study was conducted on 874 subjects in France, UK, Germany, Spain, 
Sweden, Italy, Russia, USA, Brazil, Japan, India (Hindi and English) China and South 
Africa (Zulu, Sotho and English). In the third phase, a total of 3231 subjects were 
recruited. to complete the BeautyQoL questionnaire, a skin clinical checklist, SF-36 
and a socio-demographic questionnaire. a re-test has been carried out at 8 days on a 
subgroup of 652 subjects. The database was randomly divided into two subgroups 
and analyzed using a Rash analysis. Psychometric properties, construct validity, repro-
ducibility, internal and external consistency were tested. RESULTS: From the item 
generation phase, 62 questions were selected. General acceptability was very good in 
the 16 cultures, with a very low rate of no answers. The validation phase reduced the 
questionnaire in 44 questions structured in ﬁ ve dimensions explaining 76.7% of the 
total variance: Social Life, Self conﬁ dence, Psychological life, Vitality and Seduction. 
Internal consistency was high (Cronbach alpha coefﬁ cients between 0.932 and 0.978). 
Reproducibility at 8 days was satisfactory in all dimensions. External validity testing 
revealed that BeautyQol scores correlated signiﬁ cantly with all SF-36 scores except 
for Physical Function. Mean completion time was 7 minutes (median:5 minutes). 
CONCLUSIONS: These results demonstrate the validity and reliability of the Beau-
tyQol questionnaire as the very ﬁ rst international instrument speciﬁ c to physical 
appearance. It is expected that BeautyQoL will be an instrument that will measure 
QoL affected by cosmetic products, techniques and agents that alter physical 
appearance.
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OBJECTIVES: To investigate discrepancy in the perception of dermatologic diseases 
(DD) severity between patients and physicians. METHODS: A descriptive study was 
performed: 2459 patients with DD rated their level of disease severity on a ﬁ ve level 
scale: very mild, mild, moderate, severe, very severe (PtGA). Physician global assess-
ment (PhGA) was performed on the same scale. Fifty three physicians were involved 
in an out-patient setting for three weeks (March 2010) in a dermatologic research 
hospital, Rome, Italy. RESULTS: Patients were predominantly females (59%), with 
an high education and the majority were employed; mean age was 45.9 ± 18.5 for 
females and 44.5 ± 18 for males. No discrepancy between PhGA and PtGA was 
observed in 37% of cases; PtGA under-rated compared to the physician in 35%; and 
PtGA over-rated relative to the physicians in 28%. Statistically signiﬁ cant differences 
were observed between PtGA and PhGA in each of the ﬁ ve levels of judgement (P < 
0.001). Higher percentages of patients, in respect to physicians, reported very mild, 
severe and very severe evaluations. Physicians tended to overestimate for mild and 
moderate levels. Differences were observed between male and female physicians in the 
severity judgement, reaching a statistically signiﬁ cant difference for the very mild level 
(P < 0.001) where females were more represented. CONCLUSIONS: The perceived 
severity disease in DD was different between patients and physicians and it was dif-
ferent in patients in respect to sex. Only for very mild DD there was a difference in 
PhGA between males and females, with males underestimating the severity.
PSS31
VISION-RELATED QUALITY OF LIFE INSTRUMENTS (QOL) AFTER 
REFRACTIVE CATARACT SURGERY
Tugaut B1, Meunier J1, Viala-Danten M1, Arnould B1, Berdeaux G2
1Mapi Values, Lyon, France; 2Alcon France, Rueil-Malmaison, France
OBJECTIVES: To review the available vision-related QoL instruments that could be 
used to investigate the consequences of refractive cataract surgery, in particular the 
beneﬁ t of spectacle independence. METHODS: A literature review was undertaken 
on PubMed and Embase databases using keywords “Refractive Surgical Procedures”, 
“Refractive Errors”, “Refractive”, “Questionnaire”, and “QoL”. Questionnaires were 
selected if they were developed for cataract or refractive surgery, based on the reading 
of the manuscript abstract. a further search was performed on PubMed, Embase and 
ProQolid databases to obtain information on development and psychometric valida-
tion of the questionnaires. Authors were contacted by email if missing data were 
identiﬁ ed from the published literature. Main characteristics of the questionnaires 
were described including number of items, targeted population, mode of administra-
tion, response scale, languages, and number of publications. Development methodol-
ogy was reviewed (literature review, clinician input, patient input and comprehension 
test). Psychometric properties were examined (e.g. domain description, scoring algo-
rithm, internal consistency, clinical validity, reproducibility, responsiveness). The 
above characteristics were then examined in light of the US FDA’s “Guidance for 
Industry Patient-Reported Outcome Measures: Use in Medical Product Development 
to Support Labeling Claims”. RESULTS: A total of 141 abstracts were reviewed and 
14 questionnaires were identiﬁ ed. Four instruments had both a solid development 
methodology and good psychometric properties: the CatQuest (Cataract Question-
naire), the NEI-RQL-42 (US National Eye Institute Refractive Error QoL instru-
ment-42), the NEI-VFQ-25 (US National Eye Institute Visual Function 
Questionnaire-25) and the RSVP (Refractive Status and Vision Proﬁ le). When includ-
ing the ability to assess vision-related QoL with the beneﬁ t of not wearing glasses, it 
appeared that the NEI-RQL-42 was one of the best candidates, although the beneﬁ ts 
of spectacle independence could be more deeply explored. CONCLUSIONS: Accord-
ing to this literature review, the NEI-RQL-42 could be considered as one of the best 
instruments to capture refractive vision-related QoL consequences after cataract 
surgery.
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OBJECTIVES: Estimates of the lifetime prevalence of external genital warts (EGW) 
and genital herpes in the European Union range from 0.47% to 1.52% and 0.59% 
to 1.43% respectively. The aim here is to assess, for the ﬁ rst time, the impact of the 
experience on current health related quality of life at the general population level. 
METHODS: Data are from the 2008 National Health and Wellness Survey. This is 
an internet-based survey carried out in the UK, France, Spain, Italy and Germany. 
From a total of 53,524 respondents, 521 indicated they had experienced EGW and 
520 genital herpes. Only 63 had experienced both conditions. The regression analysis 
is based on health state utilities (score 0–100) from the SF-6D. The independent 
variables included binary variables for the presence/absence of EGW and genital 
herpes, socio-demographic characteristics, health risk factors (e.g., body mass index) 
and the Charlson Comorbidity Index (CCI). RESULTS: The experience of EGW and 
genital herpes had a substantial negative impact on utility scores. The impact was 
signiﬁ cant at conventional decision levels: EGW—2.47 (95% CI: −3.58–−1.36), genital 
herpes −3.52 (95%CI: −4.63–−2.71) and EGW and genital herpes −5.00 (95%CI: 
1.76–8.25). The impact of EGW and genital herpes experience was similar to the 
negative impact of BMI for persons who were underweight, obese and morbidly obese 
and the CCI (−2.53;95%CI: −2.65–−2.41). Age, education and income all had a posi-
tive and signiﬁ cant impact on HRQoL. CONCLUSIONS: This is the ﬁ rst time the 
lifetime experience of two of the most prevalence sexually transmitted infections (STIs) 
on current HRQoL has been assessed. The results point to the continuing impact of 
this experience, with herpes having a marginally greater impact than EGWs. The 
HRQoL deﬁ cit is most apparent for those who have experienced both STIs. 
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SURVEY
Klesse M, Wolbring F
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OBJECTIVES: Evaluation of use, dose distribution, and dosing rationale of biologic 
treatments in plaque psoriasis within private practices and hospitals in Germany. 
METHODS: Fully structured Online Questionnaire using Umfragecenter® software. 
Panel participants were selected by DocCheck Medical Services using their MediAccess 
Pool. Survey was done in December 2009. 100 dermatologists (60 in private practices, 
40 in hospitals) were included in the survey. Inclusion criterion: currently treating at 
least two psoriasis patients with biologics, at least one patient on adalimumab, etan-
ercept or inﬂ iximab. RESULTS: Each surveyed dermatologist treated approximately 
100 psoriasis patients per quarter. In private practice about 10% of these patients 
were treated with a biologic, while in hospitals about 23% received biologic treatment. 
About 40% of the patients receiving a biologic suffered from psoriatic arthritis as 
well. Distribution of the different biologics used was as follows: etanercept 37%, 
adalimumab 33%, inﬂ iximab 20%, and ustekinumab 10%. Only minor differences 
in those proportions were observed between private practices and hospitals. In about 
80% of all cases, used dosing for each biologic conformed to the respective label. In 
other cases, increased dosages were observed, for example: 12% of adalimumab 
patients received 40 mg weekly, 17% of etanercept patients being treated longer than 
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24 weeks received a 50 mg BIW maintenance dose, and 23% of inﬂ iximab patients 
received infusions every 6 weeks. Reasons for dose increase included higher severity 
of disease, longer disease duration, loss of efﬁ cacy, overweight, joint involvement, 
higher number of previous systemic therapies received. CONCLUSIONS: Real-life 
dosing of psoriasis biologics does not always conform to the posology recommended 
in the product label, especially for high need patients. About 20% of patients being 
treated with a TNF-alpha-inhibitor seem to need a higher non-standard dose.
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OBJECTIVES: Finasteride is indicated for the treatment of male pattern hair loss at 
1 mg strength and for male symptomatic benign prostatic hyperplasia (BPH) at 5 mg 
strength. While the male pattern hair loss indication exclusivity does not expire until 
2013, the BPH indication expired in 2006. Patients have been known to purchase 
generic ﬁ nasteride in 5 mg strength and split the pills into quarters as a less expensive 
alternative to the branded 1 mg dose. The objective was to examine the uptake of 
generic ﬁ nasteride in relation to the prescribing volume of branded ﬁ nasteride for the 
treatment of male pattern hair loss to determine the impact of potential pill splitting 
on generic uptake and branded prescribing volume. METHODS: Generic and branded 
ﬁ nasteride were selected as case products. From 1992 to 2010 the volume of prescrip-
tions (TRx) were collected monthly using SDI’s VONA databases and grouped accord-
ing to branded and generic sales. RESULTS: Sales of generic ﬁ nasteride signiﬁ cantly 
accelerated immediately after launch. The compound average growth rate (CAGR) of 
TRx of branded 5 mg ﬁ nasteride between 1992 and 2006 was 23.29%. Meanwhile, 
the CAGR of generic 5 mg ﬁ nasteride from 2006 to 2010 was 96.17%, signaling an 
aggressive growth trend. Interestingly, the sales of branded 1 mg ﬁ nasteride were not 
impacted as they maintained steady growth with a CAGR of 2.49% over the four 
years since generic launch. CONCLUSIONS: One hypothesis as to the immediate 
growth of generic ﬁ nasteride after launch can be attributed to pill splitting; much of 
the volume increase was due to patients purchasing the much less expensive generic 
5 mg ﬁ nasteride and quartering the pills. However, if pill splitting did occur, it did 
not appear to impact sales of branded 1 mg ﬁ nasteride as demonstrated by a main-
tained steady growth in TRx. This suggests that patients who pill split may not have 
been prior users of branded 1 mg ﬁ nasteride.
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OBJECTIVES: In Germany, patients with chronic hand eczema (CHE) can either be 
treated within the statutory health insurance system, or if CHE is suspected to be 
work-related CHE in the system of occupational health insurances. The study objective 
was to analyze the cost of CHE between both systems. METHODS: The survey was 
conducted in 24 practices in the statutory health insurance system and 2 specialized 
centers of the occupational health insurances. Patients with CHE refractory to potent 
topical treatments were included. Patient characteristics/status and resource use were 
elicited from patients and physicians. Costs were evaluated from the societal perspec-
tive (using insurance speciﬁ c tariffs). Regression models were employed to compare 
the direct and indirect costs across both data sets. RESULTS: A total of 223 patients 
in the statutory health system and 87 patients in the occupational health insurance 
system were included in this study. The patients’ severity was similar across both 
samples. The yearly direct and indirect costs per patient are c1742 and c386 in the 
statutory health insurance system as well as c3309 (c2534 according to statutory 
health insurance tariff) and c3422 in the occupational health system. The indirect 
costs are more pronounced among patients with work-related CHE. a comparison of 
direct and indirect costs reveal higher costs for patients covered by occupational health 
insurances (P < 0.01); however, no cost differences between both systems can be 
detected after controlling for treatment stage and tariff differences. CONCLUSIONS: 
Differences in the costs between both systems can be explained by different treatment 
mixes, as direct costs are similar across treatment stages. As a result of longer absences 
from work, the indirect costs of patients with work-related CHE are higher. This may 
lead to the use of more effective and costly treatment strategies in this patient group.
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OBJECTIVES: Cataract surgery is one of the most efﬁ cacious medical strategies and 
one of the most frequently performed operations in developed countries. Organization 
for Economic Co-operation and Development (OECD) collects information on this 
topic but their data are not updated often. The aim of this survey was to estimate the 
number and costs of cataract surgeries performed in 14 European countries and the 
potential costs associated with astigmatism. METHODS: Cataract surgery numbers 
were estimated from available databases. Costs associated with cataract surgery were 
based on ofﬁ cial tariffs of local health care systems. The number of surgeries and the 
costs per 100 000 people were estimated for each country to allow comparisons. 
Astigmatism related costs were also explored. This survey was carried out in 14 
European countries: Austria, Belgium, Denmark, Finland, France, Germany, Greece, 
Ireland, Italy, the The Netherlands, Portugal, Spain, Sweden, and the UK. RESULTS: 
Information was fully available in 10 countries and partly available in OECD statistics. 
Cataract surgery rates were in the range of 444 to 1,006 operations per 100,000 
people in the countries with complete information. All the countries were using a DRG 
system for costs and tariffs. Costs of operations were highly variable, depending on 
complications, type of surgery, and surgical setting (outpatient or inpatient). Average 
cost of surgery ranged across the countries from c875 to c2000. Average cost per 
inhabitant was estimated at between c5 and c15 per year. Astigmatism associated 
costs are never taken into account. CONCLUSIONS: Cataract surgery is performed 
in a large part of the European population with variations across countries. Further 
research needs to be conducted to explain differences between countries.
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OBJECTIVES: Cataract surgery is one of the most efﬁ cacious medical strategies and 
one of the most frequently performed operations in developed countries. The aim of 
this survey was to establish an assessment of the available guidelines for cataract 
surgery in Europe. METHODS: The search was performed with a two steps design. 
a classical literature search was performed using the method elaborated by the French 
Haute Autorité de Santé directly through the Internet. a second step was to interview 
local experts to identify grey literature in local languages that could be available 
through local health authorities or medical societies. This survey was carried out in 
15 European countries: Austria, Belgium, Denmark, Finland, France, Germany, 
Greece, Ireland, Italy, the The Netherlands, Portugal, Spain, Sweden, Switzerland, and 
the UK. RESULTS: The classical literature search identiﬁ ed 15 documents that could 
be considered as guidelines on cataract surgery. They were mainly written in English; 
only one originated in Europe. General guidelines (n = 9) considered the initial check-
up and indications for cataract surgery, surgical techniques and follow-up. Speciﬁ c 
guidelines were found covering the type of implants (n = 1), surgical technique (n = 
1) and the anaesthesia technique (n = 4). This latter group was mainly extracted from 
the Cochrane database. The second step of the research identiﬁ ed 10 local guidelines 
in 7 European countries. These guidelines were rarely complete (n = 2) and envisaged 
some speciﬁ c aspects of the operation (n = 8) or the implants (n = 2). CONCLUSIONS: 
Guidelines on cataract surgery are available at an international level but are rarely 
provided at a country level in Europe. 
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OBJECTIVES: QoL data collected in clinical trials traditionally involves self-report 
or face to face interviewer-administered questionnaires. The former may result in 
missing data/errors; the latter requires trained interviewers, possibly adding variability 
to the data collected (when multiple sites are involved) or bias in terms of social 
desirability. To improve the quality of data collected in a clinical trial for DME, we 
employed a centralised call centre methodology. METHODS: QoL data were collected 
in a large multicenter trial, NCT00605280, evaluating the safety and efﬁ cacy of 
pegaptanib sodium in patients with DME. An interface between the trial database and 
the independent call centre was established. Once subjects entered the trial, subject 
identiﬁ er, status and visit history were automatically generated and the call centre 
agent received subject contact and visit details directly from the trial database. The 
agent contacted the subjects to schedule interviews at the appropriate time points. Five 
call backs were allowed per call to ensure questionnaire completion. All QoL responses 
were recorded directly into the call centre database. The status of the QoL visit 
information and completions were sent to the trial database weekly. RESULTS: The 
two QoL measures (National Eye Institute Visual Function Questionnaire 25 and 
EuroQol Group’s EQ-5D questionnaire) had high completion rates; 99.8% of com-
pleted interviews included both questionnaires (57% successfully completed on initial 
attempt, 23% on the second attempt of contacting the subject). Only 4% of data were 
missing; 26 minutes was the average completion time. CONCLUSIONS: This call 
centre methodology resulted in high questionnaire completion and little missing data. 
This approach demonstrates robustness and offers a feasible alternative for question-
naire administration, particularly in visually impaired people. Administration in the 
subject’s home maybe advantageous and centralised interviewers (instead of site inter-
viewers) potentially reduced the variability in questionnaire response. Further research 
comparing methods is indicated. 
